https://bsky.app/profile/ipharmaservices.bsky.socialhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mu2rlt6k4c2d#FDA가 #RevolutionMedicines 의 #RASONQUE(#daraxonrasib) 를 전이성 췌장 선암에 대해 승인했습니다. https://www.ipharmacenter.com/post/fda-approves-revolution-medicines-rasonque-for-metastatic-pancreatic-cancer-ipharmacenter #제약 #미국 #종양학 $RVMD27 Aug 2026 11:46 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mu2rlt6k4c2dhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mu2rkdwnas2d#FDA批准#RevolutionMedicines的#RASONQUE（#daraxonrasib）用于转移性胰腺腺癌。 https://www.ipharmacenter.com/post/fda-approves-revolution-medicines-rasonque-for-metastatic-pancreatic-cancer-ipharmacenter #制药 #美国 #肿瘤学 $RVMD27 Aug 2026 11:45 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mu2rkdwnas2dhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mu2rjmeclc2dA #FDA aprova o #RASONQUE (#daraxonrasib) da #RevolutionMedicines para adenocarcinoma pancreático metastático. https://www.ipharmacenter.com/post/fda-approves-revolution-medicines-rasonque-for-metastatic-pancreatic-cancer-ipharmacenter #farma #EstadosUnidos #Oncologia $RVMD27 Aug 2026 11:45 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mu2rjmeclc2dhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mu2rjakwfs2dLa #FDA approva #RASONQUE (#daraxonrasib) di #RevolutionMedicines per l’adenocarcinoma pancreatico metastatico. https://www.ipharmacenter.com/post/fda-approves-revolution-medicines-rasonque-for-metastatic-pancreatic-cancer-ipharmacenter #farmacia #StatiUniti #Oncologia $RVMD27 Aug 2026 11:45 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mu2rjakwfs2dhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mu2riq5b4k2dDie #FDA genehmigt #RASONQUE (#Daraxonrasib) von #RevolutionMedicines für metastasiertes Pankreasadenokarzinom. https://www.ipharmacenter.com/post/fda-approves-revolution-medicines-rasonque-for-metastatic-pancreatic-cancer-ipharmacenter #Pharma #VereinigteStaaten #Onkologie $RVMD27 Aug 2026 11:44 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mu2riq5b4k2dhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mu2rifpx422dLa #FDA approuve #RASONQUE (#daraxonrasib) de #RevolutionMedicines pour l’adénocarcinome pancréatique métastatique. https://www.ipharmacenter.com/post/fda-approves-revolution-medicines-rasonque-for-metastatic-pancreatic-cancer-ipharmacenter #pharma #ÉtatsUnis #Oncologie $RVMD27 Aug 2026 11:44 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mu2rifpx422dhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mu2rhzxvvk2d#LaFDA aprueba #RASONQUE (#daraxonrasib) de #RevolutionMedicines para el adenocarcinoma pancreático metastásico. https://www.ipharmacenter.com/post/fda-approves-revolution-medicines-rasonque-for-metastatic-pancreatic-cancer-ipharmacenter #farmacia #EstadosUnidos #Oncología $RVMD27 Aug 2026 11:44 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mu2rhzxvvk2dhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mu2rhjz65k2d#FDA approves #RevolutionMedicines’ #RASONQUE (#daraxonrasib) for metastatic #pancreaticadenocarcinoma https://www.ipharmacenter.com/post/fda-approves-revolution-medicines-rasonque-for-metastatic-pancreatic-cancer-ipharmacenter #pharma #unitedstates #Oncology $RVMD27 Aug 2026 11:44 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mu2rhjz65k2dhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mtyptb6gik2dLa #NMPA en #Chine a approuvé l'injection de #Rexobin (Shanghai Huatai Biological Pharmacy) en procédure prioritaire pour adultes (≥40kg) avec poussées de #psoriasis pustuleux généralisé https://www.ipharmacenter.com/post/china-nmpa-approves-new-therapies-2026 #Dermatology #RareDiseases #Pharma #healthcare26 Aug 2026 16:09 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mtyptb6gik2dhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mtypsdh7222dLa #NMPA de #China aprobó la inyección de #Rexobin (Shanghai Huatai Biological Pharmacy) por vía prioritaria para adultos (≥40kg) con brotes de #psoriasis pustulosa generalizada https://www.ipharmacenter.com/post/china-nmpa-approves-new-therapies-2026 #Dermatology #RareDiseases #Pharma #healthcare26 Aug 2026 16:09 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mtypsdh7222dhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mtyihbykf22dLa #NMPA autorise l'injection Rexobin (Shanghai Huatai Bio / SHA: 600521) en procédure prioritaire contre les poussées de #psoriasis pustuleux généralisé chez l'adulte (≥40kg) https://www.ipharmacenter.com/post/china-nmpa-approves-new-therapies-2026 #NMPA #Psoriasis #Dermatologie #Pharma26 Aug 2026 13:57 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mtyihbykf22dhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mtyigeabq22d国家药监局优先审评批准上海华泰生物 的瑞索宾注射液，用于治疗成人泛发性脓疱型银屑病发作。 https://www.ipharmacenter.com/post/china-nmpa-approves-new-therapies-2026 #NMPA #银屑病 #罕见病 #新药批准26 Aug 2026 13:57 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mtyigeabq22dhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mtyifjjuvs2dLa #NMPA aprobó la inyección #Rexobin (Shanghai Huatai Bio) por vía prioritaria para brotes de #psoriasis pustulosa generalizada en adultos (≥40kg). https://www.ipharmacenter.com/post/china-nmpa-approves-new-therapies-2026 #NMPA #Psoriasis #Dermatologia #EnfermedadesRaras26 Aug 2026 13:56 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mtyifjjuvs2dhttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mty4b43ovs23#EU가 PD-L1 양성 전이성 삼중음성 #유방암의 1차 치료제로 #Gilead의 #Trodelvy와 #pembrolizumab 병용요법을 승인했습니다. $GILD $MRK https://www.ipharmacenter.com/post/european-commission-ema-drug-approvals-2026-ipharmacenter #TNBC #종양학 #유럽뉴스 #유럽연합집행위원회26 Aug 2026 10:19 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mty4b43ovs23https://bsky.app/profile/ipharmaservices.bsky.social/post/3mty4aigl3223#EUは、PD-L1陽性の転移性トリプルネガティブ#乳がんの一次治療として、#Gileadの#Trodelvyと#pembrolizumabの併用を承認しました。 $GILD $MRK https://www.ipharmacenter.com/post/european-commission-ema-drug-approvals-2026-ipharmacenter #TNBC #腫瘍学 #欧州ニュース #欧州委員会26 Aug 2026 10:19 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mty4aigl3223https://bsky.app/profile/ipharmaservices.bsky.social/post/3mty4a3qqqk23#欧盟批准#Gilead的#Trodelvy联合#pembrolizumab，用于PD-L1阳性转移性三阴性#乳腺癌的一线治疗。 $GILD $MRK https://www.ipharmacenter.com/post/european-commission-ema-drug-approvals-2026-ipharmacenter #TNBC #肿瘤学 #欧洲新闻 #欧盟委员会26 Aug 2026 10:18 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mty4a3qqqk23https://bsky.app/profile/ipharmaservices.bsky.social/post/3mty47k725223A #UE aprova o #Trodelvy da #Gilead com #pembrolizumabe como tratamento de primeira linha para câncer de #mama triplo negativo metastático PD-L1 positivo. $GILD $MRK https://www.ipharmacenter.com/post/european-commission-ema-drug-approvals-2026-ipharmacenter #TNBC #Oncologia #NotíciasDaEuropa #ComissãoEuropeia26 Aug 2026 10:18 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mty47k725223https://bsky.app/profile/ipharmaservices.bsky.social/post/3mty47bzrrs23#LUE approva #Trodelvy di #Gilead in combinazione con #pembrolizumab come trattamento di prima linea per il carcinoma #mammario triplo negativo metastatico PD-L1 positivo. $GILD $MRK https://www.ipharmacenter.com/post/european-commission-ema-drug-approvals-2026-ipharmacenter #TNBC #Oncologia #NotizieEuropee #CommissioneEuropea26 Aug 2026 10:18 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mty47bzrrs23https://bsky.app/profile/ipharmaservices.bsky.social/post/3mty46lhfl223Die #EU genehmigt #Trodelvy von #Gilead zusammen mit #Pembrolizumab als Erstlinientherapie bei PD-L1-positivem metastasiertem triple-negativem #Brustkrebs. $GILD $MRK https://www.ipharmacenter.com/post/european-commission-ema-drug-approvals-2026-ipharmacenter #TNBC #Onkologie #EuropaNachrichten #EuropäischeKommission26 Aug 2026 10:18 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mty46lhfl223https://bsky.app/profile/ipharmaservices.bsky.social/post/3mty46egdgc23#LUE approuve le #Trodelvy de #Gilead associé au #pembrolizumab en première ligne du cancer du #sein triple négatif métastatique PD-L1 positif. $GILD $MRK https://www.ipharmacenter.com/post/european-commission-ema-drug-approvals-2026-ipharmacenter #TNBC #Oncologie #ActualitésEuropéennes #CommissionEuropéenne26 Aug 2026 10:17 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mty46egdgc23https://bsky.app/profile/ipharmaservices.bsky.social/post/3mty45johq223#LaUE aprueba #Trodelvy de #Gilead más #pembrolizumab para el tratamiento de primera línea del cáncer de #mama triple negativo metastásico PD-L1 positivo. $GILD $MRK https://www.ipharmacenter.com/post/european-commission-ema-drug-approvals-2026-ipharmacenter #TNBC #Oncología #NoticiasDeEuropa #ComisiónEuropea26 Aug 2026 10:17 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mty45johq223https://bsky.app/profile/ipharmaservices.bsky.social/post/3mty44zm7oc23#EU approves #Gilead’s #Trodelvy plus #pembrolizumab for first-line PD-L1-positive metastatic triple-negative #breastcancer $GILD $MRK https://www.ipharmacenter.com/post/european-commission-ema-drug-approvals-2026-ipharmacenter #TNBC #Oncology #EuropeNews #EuropeanCommission26 Aug 2026 10:17 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mty44zm7oc23https://bsky.app/profile/ipharmaservices.bsky.social/post/3mty33irer223FDA menyetujui IMAAVY, atau nipocalimab, sebagai terapi pertama yang khusus disetujui untuk anemia hemolitik autoimun hangat pada pasien berusia 12 tahun ke atas. ENERGY: respons hemoglobin 23,7% vs 7,7% dengan plasebo. $JNJ https://www.ipharmacenter.com/post/fda-approves-johnson-and-johnson-s-imaavy-for-warm-autoimmune-hemolytic-anemia-ipharmacenter #PenyakitLangka #Hematologi26 Aug 2026 09:58 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mty33irer223https://bsky.app/profile/ipharmaservices.bsky.social/post/3mty337vnns23FDA가 12세 이상 온난 자가면역 용혈성 빈혈 환자를 위한 최초 승인 치료제로 IMAAVY, 즉 nipocalimab을 승인했습니다. ENERGY: 헤모글로빈 반응 23.7%, 위약군 7.7%. $JNJ https://www.ipharmacenter.com/post/fda-approves-johnson-and-johnson-s-imaavy-for-warm-autoimmune-hemolytic-anemia-ipharmacenter #희귀질환 #혈액학26 Aug 2026 09:58 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mty337vnns23https://bsky.app/profile/ipharmaservices.bsky.social/post/3mty2y4a3as23#FDA approves #IMAAVY, or #nipocalimab, as the first treatment specifically authorized for warm autoimmune hemolytic #anemia in patients aged 12+ ENERGY: hemoglobin response 23.7% vs 7.7% with PBO https://www.ipharmacenter.com/post/fda-approves-johnson-and-johnson-s-imaavy-for-warm-autoimmune-hemolytic-anemia-ipharmacenter $JNJ #RareDisease #Hematology26 Aug 2026 09:56 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mty2y4a3as23https://bsky.app/profile/ipharmaservices.bsky.social/post/3mttshsuxws2tLos 10 #medicamentos más vendidos de 2025 generaron >$180B. #Keytruda lidera con $31,7B, seguido de #Mounjaro ($23B) y #Ozempic ($20B). #EliLilly domina los ingresos totales con $36,5B en 2 puestos. https://www.ipharmacenter.com/post/the-pharma-top-10-highest-revenue-drugs-of-2025-official-sales-data-analysis #Farma #Oncología $MRK24 Aug 2026 17:13 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mttshsuxws2thttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mttplcs4422t#日本 已批准 #GSK 用于治疗慢性 #乙肝 的 #Hibsago 以及 #武田 用于治疗1型 #发作性睡病 的 #Orzeyful https://www.ipharmacenter.com/post/japan-approves-gsk-s-hibsago-for-chronic-hepatitis-b-and-takeda-s-orzeyful-for-narcolepsy-type-1 #日本 #新闻 #媒体 #医药 #医疗健康 #生物医药24 Aug 2026 16:21 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mttplcs4422thttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mttpksmqgs2t#日本 が慢性 #B型肝炎 治療薬として #GSK の #ヒブサゴ （#Hibsago）、#ナルコレプシー 1型治療薬として #武田薬品 の #オーゼイフル （#Orzeyful）を承認 https://www.ipharmacenter.com/post/japan-approves-gsk-s-hibsago-for-chronic-hepatitis-b-and-takeda-s-orzeyful-for-narcolepsy-type-1 #日本 #ニュース #メディア #製薬 #ヘルスケア24 Aug 2026 16:21 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mttpksmqgs2thttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mttpkbmy2c2tIl #Giappone ha approvato #Hibsago di #GSK per l'#epatiteB cronica e #Orzeyful di #Takeda per la #narcolessia di tipo 1 https://www.ipharmacenter.com/post/japan-approves-gsk-s-hibsago-for-chronic-hepatitis-b-and-takeda-s-orzeyful-for-narcolepsy-type-1 #Giappone #Notizie #Media #Pharma #Salute #Farmaceutica24 Aug 2026 16:21 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mttpkbmy2c2thttps://bsky.app/profile/ipharmaservices.bsky.social/post/3mttpjoiclc2tO #Japão aprovou o #Hibsago da #GSK para #hepatiteB crônica e o #Orzeyful da #Takeda para #narcolepsia tipo 1 https://www.ipharmacenter.com/post/japan-approves-gsk-s-hibsago-for-chronic-hepatitis-b-and-takeda-s-orzeyful-for-narcolepsy-type-1 #Japao #Noticias #Midia #Farma #Saude #Farmaceutica24 Aug 2026 16:21 +0000at://did:plc:m2b7vanjpfezprcagixv2cxi/app.bsky.feed.post/3mttpjoiclc2t